Mild Autonomous Cortisol Secretion (MACS)
7
4
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
29%
2 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS